Severe Pulmonary Hypertension Due to Adult-Onset Still’s Disease

Ankur Sinha, MBBS1, Ravikaran Patti, MBBS1, Paurush Ambesh, MBBS1, Chukwudi Obiagwu, MD1, Namrita Malhan, BDS2, and Kabu Chawla, MD1

Abstract
A 29-year-old female with adult-onset Still’s disease (AOSD) presented with progressive shortness of breath both on rest and on exertion, increased abdominal girth, and swelling in both legs. She was on oral prednisone and was recently started on canakinumab (interleukin-1 antagonist) for joint pain and rash of AOSD. Echocardiogram showed severely dilated right ventricle, dilated pulmonary artery, moderately reduced right ventricular systolic function, but with normal left ventricular systolic function. Computed tomography with contrast ruled out pulmonary embolism. Blood tests ruled out other rheumatologic diseases. The patient was diagnosed with right-sided heart failure likely secondary to AOSD. Right heart catheterization was needed but could not be performed because of severely dilated pulmonary artery. The patient was transferred to a higher center for further management and possible cardiopulmonary transplant.

Keywords
pulmonary hypertension, adult-onset Still’s disease

Introduction
Adult-onset Still’s disease (AOSD) is a rare inflammatory autoimmune disease that is classically described by “Still’s triad” of fever, maculopapular rash, and arthritis, but it also has other atypical features like leukocytosis, elevated liver enzymes, and high serum ferritin levels.1 The etiology remains largely unknown.

Pulmonary arterial hypertension (PAH) is a disease characterized by progressive constriction of pulmonary arteries, thereby causing an elevation in pulmonary arterial resistance and pressure. Although PAH has been reported with connective tissue disorders like systemic lupus erythematosus and systemic sclerosis, its association with AOSD is very rare.

Case Report
A 29-year-old female with AOSD presented with shortness of breath at rest. Her symptoms had progressed over 3 months. She complained of increased abdominal girth with swelling in both her legs. She had a history of poorly controlled AOSD with frequent flares leading to joint pain and rash. On discussion with the patient’s primary rheumatologist, we gathered that the patient had met criteria for diagnosis of AOSD (Yamaguchi criteria). The major criteria met were intermittent arthralgia lasting more than 4 weeks and leukocytosis as high as 13 000/mm with 91% neutrophils without evidence of infection. The minor criteria satisfying the diagnosis of AOSD were cervical lymphadenopathy on presentation, abnormal liver function tests (raised alkaline phosphatase to 138 U/L, aspartate aminotransferase of 75 U/L, and alanine aminotransferase of 60 U/L), a negative antinuclear antibody, and a negative rheumatoid factor. She met 5 criteria of AOSD with 2 major and 3 minor criteria. Workup for other rheumatologic conditions including systemic lupus erythematosus, systemic sclerosis, and CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome was negative. She was initially started on prednisone followed by conventional disease-modifying antirheumatoid drugs with little benefit. She had a previous trial of anakinra (interleukin-1 [IL] antagonist) as well as canakinumab (IL-1 antagonist) with no clinical improvement.

On admission, posteroanterior radiograph of the chest showed an enlarged cardiac silhouette with bilateral pleural effusions. Echocardiogram showed severely dilated pulmonary...
artery with dilated right ventricle. The estimated right ventricular systolic pressure was markedly elevated to 74.64 mm Hg, with moderately reduced right ventricular systolic function. Left ventricular systolic function was normal with an ejection fraction of 56% to 60%. The patient also had bilateral pleural effusion for which chest tubes were placed. Computed tomography with contrast ruled out pulmonary embolism, but the findings were significant for severely dilated pulmonary arterial trunk (Figures 1 and 2). Rheumatoid factor and antinuclear antibody were negative. Anti-dsDNA antibody was negative. The patient had evidence of active inflammation; serum ferritin was very high: 1167.5 ng/mL (normal 11-306 ng/mL in females). Complement levels were obtained, C3 level was low at 65 mg/dL (normal 80-180 mg/dL) and C4 level was normal at 11 mg/dL (normal 10-45). Erythrocyte sedimentation rate was 9 mm/h, and C-reactive protein was 1.43 mg/L.

The patient was diagnosed with probable PAH with evidence of right heart failure. Right heart catheterization was considered, but could not be performed because of severely dilated pulmonary artery. Chest tubes were removed and the patient was transferred to a tertiary care center equipped to provide cardiopulmonary transplant.

**Discussion**

AOSD is a clinical diagnosis, and an exclusion of other systemic disorders has to be carried out. The triad of fever, rash, and arthritis (Still’s triad) can be associated with macrophage activation syndrome, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and diffuse alveolar hemorrhage. The Yamaguchi criteria for diagnosis of AOSD are summarized in Table 1. Apart from these criteria, elevated ferritin levels can also aid in the diagnosis of AOSD.

| Major criteria | • Fever >39°C, lasting 1 week or longer |
|----------------|----------------------------------------|
|                | • Arthralgia or arthritis, lasting 2 weeks or longer |
|                | • Typical rash |
|                | • Leukocytosis >10 000/mm with >80% polymorphonuclear cells |
| Minor criteria | • Sore throat |
|                | • Recent development of significant lymphadenopathy |
|                | • Hepatomegaly or splenomegaly |
|                | • Abnormal liver function tests |
|                | • Negative tests for antinuclear antibody and rheumatoid factor (IgM) |
| Exclusion criteria | • Infections |
|                | • Malignancies |
|                | • Other rheumatic diseases |

Five or more criteria are required with 2 or more being major criteria for diagnosis of AOSD.

Abbreviations: AOSD, adult-onset Still’s disease; IgM, immunoglobulin M.
Echocardiography can suggest PAH with estimation of pulmonary artery pressure as well as right ventricular systolic pressure. Computed tomography scan of the chest may be performed to rule out interstitial lung involvement, or pathology favoring the diagnosis of other systemic diseases. Definitive diagnosis of PAH remains right heart catheterization with measurement of pulmonary capillary wedge pressure.

Survival after onset of PAH in patients with connective tissue diseases is shorter in comparison to idiopathic PAH. There have been no randomized clinical trials comparing treatment modalities for PAH secondary to AOSD and other connective tissue disorders, thus treatment is in the same lines as idiopathic PAH. Systemic inflammation plays a key role in the disease process of AOSD causing PAH. This is evident in studies that compared the use of anti-inflammatory/immunosuppressive therapy in conjunction with vasodilator therapies, and showed a significantly better response rate in comparison to vasodilator therapy alone.

Treatment of PAH is aimed at the primary cause of disease, but Group 1 PAH often needs advanced therapy. There are reports of clinical improvement of PAH with immunosuppressive therapy, and advanced therapy inclusive of endothelin receptor blockers, prostanoids, and phosphodiesterase-5 inhibitors have been associated with improvement in exercise tolerance and pulmonary hemodynamics. IL-1 receptor antagonists (anakinra) has been reported to cause rapid regression of disease. IL-6 inhibitor use (tocilizumab) has been proposed for AOSD based on the disease pathology.

Suggested treatment modalities based on our literature review have been summarized in Table 2.

### Learning Points
- AOSD has been associated with PAH on rare occasions.
- Physicians should keep a vigil watch for respiratory symptoms like shortness of breath, cough, and pleuritic chest pain in a patient with AOSD.
- Specific therapy like anakinra and canakinumab should be attempted in addition to steroids.
- Early referral to higher centers equipped in dealing with pulmonary hypertension, heart failure, and possible cardiopulmonary transplant can be lifesaving.

### Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

### Ethical Approval
Ethical approval was not required as per institutional guidelines. Patient anonymity has been maintained throughout the article and images.

---

### Table 2. Suggested Treatment Modalities for PAH Due to AOSD Group 1 PAH.

| Drug Group                                                                 | Mechanism of Action                        | Example                        |
|---------------------------------------------------------------------------|--------------------------------------------|--------------------------------|
| Primary therapy                                                           |                                            |                                |
| Oral steroids                                                             | Immunosuppressive                          | Prednisone                      |
| DMARD                                                                     | Immunosuppressive                          | Methotrexate                    |
|                                                                          |                                            | Cyclosporine                    |
| Drugs aimed at pulmonary hemodynamics                                     |                                            |                                |
| Calcium channel blockers                                                  | Vasodilation, improved 5-year survival    | Dihydropyridine                 |
|                                                                          |                                            | Diltiazem                       |
| Prostaglandin analogs                                                     | Vasodilation                               | Epoprostol (continuous IV)      |
|                                                                          |                                            | Treprostinil (IV and subcutaneous) |
|                                                                          |                                            | Selexipab (oral)                |
| Endothelin antagonists                                                    | Vasodilation—vasoconstrictive and a mitogen | Bosentan (nonselective)         |
| Drugs aimed at pulmonary hemodynamics                                     |                                            |                                |
| Nitric oxide–cyclic guanosine monophosphate enhancers                     | Vasodilation                               | Ambisentan (selective)          |
|                                                                          |                                            | Sildenafil                      |
|                                                                          |                                            | Tadalafil                       |
| Biological agents aimed at AOSD                                           |                                            |                                |
| Interleukin-1 antagonist                                                   | Cytokine blockade                          | Anakinra                        |
|                                                                          |                                            | Canakinumab                     |
| Interleukin-6 antagonist                                                   | Cytokine blockade                          | Tocilizumab                     |

Abbreviations: PAH, pulmonary arterial hypertension; AOSD, adult-onset Still’s disease; DMARD, disease-modifying antirheumatic drug; IV, intravenous.
**Informed Consent**

Informed consent was obtained.

**ORCID iD**

Ankur Sinha https://orcid.org/0000-0002-6245-3115

**References**

1. Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. *Clin Rheumatol*. 2014;33:305-314. doi:10.1007/s10067-014-2487-4.
2. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. *J Rheumatol*. 1992;19:424-430.
3. Schwarz-Eywill M, Heilig B, Bauer H, Breitbart A, Pezzutto A. Evaluation of serum ferritin as a marker for adult Still’s disease activity. *Ann Rheum Dis*. 1992;51:683-685.
4. Weatherald J, Lategan J, Helmersen D. Pulmonary arterial hypertension secondary to adult-onset Still’s disease: response to cyclosporine and sildenafil over 15 years of follow-up. *Respir Med Case Rep*. 2016;19:27-30. doi:10.1016/j.rmcr.2016.06.007.
5. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(25 suppl):D34-D41. doi:10.1016/j.jacc.2013.10.029.
6. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. *Chest* 2012;141:210-221.
7. Ngian GS, Stevens W, Prior D, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. *Arthritis Res Ther*. 2012;14:R213.
8. Distler O, Pignone A. Pulmonary arterial hypertension and rheumatic diseases—from diagnosis to treatment. *Rheumatology (Oxford)*. 2006;45(suppl 4):iv22-iv25.
9. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. *Arthritis Rheum*. 2008;58:521-531.
10. Campos M, Schiopu E. Pulmonary arterial hypertension in adult-onset Still’s disease: rapid response to anakinra. *Case Rep Rheumatol*. 2012;2012:537613. doi:10.1155/2012/537613.